How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,810 results for

Antipsychotic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. (PubMed)

Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments (...) of Trials including the registries of clinical trials (16 July 2015 and 26 April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information.We included reports identified in the search if they were controlled trials dealing with people with antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illness who had been randomly allocated to (a) anticholinergic medication versus placebo

2018 Cochrane

2. Cholinergic medication for antipsychotic-induced tardive dyskinesia. (PubMed)

Cholinergic medication for antipsychotic-induced tardive dyskinesia. Tardive dyskinesia (TD) remains a troublesome adverse effect of conventional antipsychotic (neuroleptic) medication. It has been proposed that TD could have a component of central cholinergic deficiency. Cholinergic drugs have been used to treat TD.To determine the effects of cholinergic drugs (arecoline, choline, deanol, lecithin, meclofenoxate, physostigmine, RS 86, tacrine, metoxytacrine, galantamine, ipidacrine, donepezil (...) , rivastigmine, eptastigmine, metrifonate, xanomeline, cevimeline) for treating antipsychotic-induced TD in people with schizophrenia or other chronic mental illness.An electronic search of the Cochrane Schizophrenia Group's Study-Based Register of Trials (16 July 2015 and April 2017) was undertaken. This register is assembled by extensive searches for randomised controlled trials in many electronic databases, registers of trials, conference proceedings and dissertations. References of all identified studies

2018 Cochrane

3. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial (PubMed)

Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) Care and Public Health, Brighton and Sussex Medical School, Mayfield House, University of Brighton, Brighton, UK 3 Services Psychiatriques, Jura bernois, Bienne-Seeland, Bellelay, Switzerland 4 Department of Social Policy, London School of Economics and Political Science, London, UK 5 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK * Corresponding author Email: {{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published

Full Text available with Trip Pro

2016 NIHR HTA programme

4. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. (PubMed)

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar

Full Text available with Trip Pro

2016 Cochrane

5. Antipsychotic medications for cocaine dependence. (PubMed)

Antipsychotic medications for cocaine dependence. Cocaine dependence is a public health problem characterised by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists.To evaluate the efficacy and the acceptability of antipsychotic medications for cocaine dependence.This review is an update of a previous Cochrane review published in 2007. We searched up to 15 July 2015 in Cochrane (...) Drugs and Alcohol Group Specialised Register (searched in CRSLive); the Cochrane Library (including the Cochrane Central Register of Controlled Trials (CENTRAL); the Database of Abstracts of Reviews of Effects (DARE)); PubMed; EMBASE; CINAHL and Web of Science. All searches included non-English language literature.All randomised controlled trials and controlled clinical trials with focus on the use of any antipsychotic medication for the treatment of cocaine dependence.We used standard

Full Text available with Trip Pro

2016 Cochrane

6. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. (PubMed)

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known (...) to influence the catecholaminergic system at various junctures.1. To determine the effects of any of the following drugs for antipsychotic-induced TD in people with schizophrenia or other chronic mental illnesses.i. Drugs which influence the noradrenergic system.ii. Dopamine receptor agonists.iii. Dopamine receptor antagonists.iv. Dopamine-depletor drugs.v. Drugs that increase the production or release of dopamine.2. To examine whether any improvement occurred with short periods of intervention (less than

2018 Cochrane

7. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. (PubMed)

Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have (...) medication favouring switch to quetiapine compared with switch to haloperidol (1 RCT, 45 people, RR 0.45 CI 0.21 to 0.96, low-quality evidence). There was no evidence of a difference for switch to risperidone or haloperidol compared with antipsychotic cessation (with placebo) (RR 1 RCT, 48 people, RR 2.08 95% CI 0.74 to 5.86, low-quality evidence) and switch to risperidone compared with switch to haloperidol (RR 1 RCT, 37 people, RR 0.68 95% CI 0.34 to 1.35, very low-quality evidence).Trials also

2018 Cochrane

8. Metformin as prevention in people taking antipsychotic medication

Metformin as prevention in people taking antipsychotic medication Metformin as prevention in people taking antipsychotic medication – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2016\/06\/whitepills.jpg"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 14 2016 Metformin as prevention in people (...) taking antipsychotic medication By in , , , , Journal reference: Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2015 Oct;35(5):499-509. Link: Published: October 2015 Evidence cookie says… The effect of metformin on cardiovascular disease in people living without diabetes on long-term antipsychotic medication is unknown

2016 Morsels of Evidence

9. What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication. (PubMed)

What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication. Capturing service users' perspectives can highlight additional and different concerns to those of clinicians, but there are no up to date, self-report psychometrically sound measures of side effects of antipsychotic medications. Aim To develop a psychometrically sound measure to identify antipsychotic side effects important to service users (...) by patients. Identifying key side effects important to patients can act as a starting point for joint decision making on the type and the dose of medication.

Full Text available with Trip Pro

2017 Psychological Medicine

10. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes

Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes Some atypical antipsychotics are associated with metabolic side effects, which are risk factors for gestational diabetes. The authors examined the risk of developing gestational diabetes associated with the continuation of treatment with aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine during pregnancy compared with discontinuation of these antipsychotic (...) antipsychotic medication before the start of pregnancy, women who continued treatment with olanzapine or quetiapine had an increased risk of gestational diabetes that may be explained by the metabolic effects associated with these two drugs.

2018 EvidenceUpdates

11. Use of Antipsychotic Drugs by Elderly Primary Care Patients and the Effects of Medication Reviews: A Cross-Sectional Study in Sweden (PubMed)

Use of Antipsychotic Drugs by Elderly Primary Care Patients and the Effects of Medication Reviews: A Cross-Sectional Study in Sweden Antipsychotics form a class of drugs that should be used with caution among elderly people because of a high risk of adverse events. Despite the risks and modest effects, their use is estimated to be high, especially in nursing homes.The aim was to explore the effects of medication reviews on antipsychotic drug use for elderly primary care patients and describe (...) the extent of, and reasons for, the prescription of antipsychotics.In this cross-sectional study in primary care in Skåne, Sweden, patients aged ≥75 years living in nursing homes or in their own homes with home care were included. The effects of medication reviews were documented, as were the use of antipsychotics and the differences in characteristics between patients receiving or not receiving antipsychotics.A total of 1683 patients aged 87.6 (±5.7) years were included in the analysis. Medication

Full Text available with Trip Pro

2017 Drugs - real world outcomes

12. Anticholinergic burden before and after hospitalization in older adults with dementia: increase due to antipsychotic medications. (PubMed)

Anticholinergic burden before and after hospitalization in older adults with dementia: increase due to antipsychotic medications. To evaluate changes in the use of antipsychotics and medications with anticholinergic activity (MACs) during hospitalization in older adults with dementia and factors associated with antipsychotic prescriptions and increased anticholinergic burden (ACB).This retrospective cohort study included all patients aged ≥65 years with a discharge diagnosis of dementia (...) hospitalized at the university hospital of Udine, Italy, 2012-2014. Medications dispensed within 3 months before and after hospitalization, respectively, were identified in community-pharmacy dispensations while those prescribed at discharge were collected from Hospital Electronic Medical Records (EMR). ACB was assessed using the Anticholinergic Cognitive Burden score.Among 1,908 patients included, at discharge 37.0% used ≥1 antipsychotic (9.4% before and 12.6% after hospitalization), 68.6% used ≥1 MAC

2019 International Journal of Geriatric Psychiatry

13. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. (PubMed)

The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications.Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from

2019 Current medical research and opinion

14. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. (PubMed)

Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Weight gain during treatment with antipsychotics is a prominent side-effect, especially with some second-generation antipsychotics, such as olanzapine and clozapine, and pharmacological treatments which ameliorate this side-effect are important to investigate. Decreases in histaminergic transmission in the brain induced by antipsychotics may be one (...) antagonists, such as olanzapine or clozapine, but may not be useful for this purpose in patients on other antipsychotic medications. The results justify larger placebo-controlled studies to further confirm these effects before specific recommendations can be made for routine use.

2019 Psychopharmacology

15. A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity

A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity Weight gain and other metabolic sequelae of antipsychotic medications can lead to medication non-adherence, reduced quality of life, increased costs, and premature mortality. Of the approaches to address this, behavioral interventions are less invasive, cost less, and can result in sustained long-term benefits.We investigated behavioral weight (...) management interventions for veterans with mental illness across four medical centers within the Veterans Affairs (VA) Healthcare System.We conducted a 12-month, multi-site extension of our previous randomized, controlled study, comparing treatment and control groups.Veterans (and some non-veteran women) diagnosed with mental illness, overweight (defined as having a BMI over 25), and required ongoing antipsychotic therapy.One group received "Lifestyle Balance" (LB; modified from the Diabetes Prevention

Full Text available with Trip Pro

2017 EvidenceUpdates

16. Intermittent antipsychotic medication and mortality in institutionalized older adults: A scoping review. (PubMed)

Intermittent antipsychotic medication and mortality in institutionalized older adults: A scoping review. Antipsychotic use appears to increase mortality risk among older adults with dementia. Whether this risk is similar for regular or intermittent use is unknown. This scoping review aims to explore the temporal association between antipsychotic use and mortality risk for older institutionalized adults.We conducted a scoping review using Medline (PubMed), EMBASE, CINAHL, and the Cochrane (...) libraries between October 2018 and January 2019.Twenty-eight articles met review criteria. We found that different antipsychotic medications present different safety profiles. The risk of mortality was highest with conventional antipsychotic use and within 40 days of antipsychotic initiation.Conventional antipsychotic use increases mortality for older institutionalized adults. The evidence for atypical antipsychotics is less clear. Mortality risk appears highest within 30 to 40 days of initiating

Full Text available with Trip Pro

2019 International Journal of Geriatric Psychiatry

17. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. (PubMed)

Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated by enrollment in a cluster-randomized LAI clinical trial.Eligible patients aged 18-35 years with a DSM-5 diagnosis of schizophrenia and less than 5 (...) years of lifetime antipsychotic use were recruited between December 2014 and December 2016. Training for LAI antipsychotic site staff included education regarding the role of nonadherence in relapse/hospitalization and the rationale for LAI antipsychotic use with early-psychosis patients, training in shared decision-making and communication strategies, review of frequently asked questions about LAI antipsychotics, and role-playing to develop skills and solutions to overcoming LAI antipsychotic

2019 Journal of Clinical Psychiatry

18. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. (PubMed)

Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Antipsychotic medication reduces the severity of serious mental illness (SMI) and improves patient outcomes only when medicines were taken as prescribed. Nonadherence to the treatment of SMI increases the risk of relapse and hospitalization and reduces the quality of life. It is necessary to understand the factors influencing (...) nonadherence to medication in order to identify appropriate interventions. This systematic review assessed the published evidence on modifiable reasons for nonadherence to antipsychotic medication in patients with SMI.Articles published between January 1, 2005, and September 10, 2015, were searched on MEDLINE through PubMed. Abstracts were independently screened by 2 randomly assigned authors for inclusion, and disagreement was resolved by another author. Selected full-text articles were divided among all

Full Text available with Trip Pro

2017 Patient preference and adherence

19. Nonpharmacological Interventions Targeted at Delirium Risk Factors, Delivered by Trained Volunteers (Medical and Psychology Students), Reduced Need for Antipsychotic Medications and the Length of Hospital Stay in Aged Patients Admitted to an Acute Interna (PubMed)

Nonpharmacological Interventions Targeted at Delirium Risk Factors, Delivered by Trained Volunteers (Medical and Psychology Students), Reduced Need for Antipsychotic Medications and the Length of Hospital Stay in Aged Patients Admitted to an Acute Interna Purpose. Effectiveness of nonpharmacological multicomponent prevention delivered by trained volunteers (medical and psychology students), targeted at delirium risk factors in geriatric inpatients, was assessed at an internal medicine ward (...) complications to the intervention group. The control group, selected using a retrospective individual matching strategy (1 : 1 ratio, regarding age, gender, and time of hospitalization), received standard care. Outcome Measures. Hospitalization time, deaths, falls, delirium episodes, and antipsychotic prescriptions were assessed retrospectively from medical documentation. Results. 130 patients (38.4% males) participated in the study, with 65 in the intervention group. Antipsychotic medications were

Full Text available with Trip Pro

2017 BioMed research international

20. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. (PubMed)

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference (...) in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium. Paliperidone palmitate once monthly, risperidone microspheres, haloperidol decanoate, and olanzapine pamoate were studied. This study demonstrated significantly higher treatment continuation of paliperidone palmitate once monthly compared to risperidone microspheres (p-value<0,01

Full Text available with Trip Pro

2017 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>